AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUL 25 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - A new report in Vaccine heralds the arrival of a monoclonal antibody (mAb) vaccine that protects mice against challenge with a human urogenital strain of chlamydia.
J.A. Whittum-Hudson described the difficulties of three decades of antichlamydia vaccine research that have yet to produce a candidate that can protect against heterologous challenge or infectious challenge at more than one site.
"The majority of experimental anti-chlamydial vaccines to date have targeted the chlamydial major outer membrane protein (MOMP)," wrote Whittum-Hudson and colleagues. "Many MOMP-directed vaccine candidates have been highly immunogenic, but have failed to protect against infectious challenge."
The researchers extended previous studies of a different antichlamydia vaccine, a monoclonal anti-idiotypic antibody (anti-Id; mAb2), which is a molecular mimic of the chlamydial glycolipid exoantigen (GLXA).
Oral, nasal, and subcutaneous inoculations with the poly (lactide) encapsulated-mAb2 to GLXA protected C3H/HeJ mice against topical vaginal challenge with a human strain of C. trachomatis (K serovar; UW-31).
GLXA-specific and anti-EB neutralizing serum antibodies were associated with reduced vaginal shedding and genital tract inflammation ("The anti-idiotypic antibody to chlamydial ...